India, June 9 -- Shares of Metsera, Inc. (MTSR) gained over 20% on Monday morning after the company announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.
MTSR is currently trading $33.00, up $5.51 or 20.04%, on the Nasdaq. The stock opened its trading at $31.60 after closing Friday at $27.49. The stock has traded between $12.30 and $35.19 in the past 52-week period.
In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tol...